Generate Biomedicines reports Q2 2026 results, advances asthma and oncology pipeline
Phase 3 asthma trials expand recruitment and an oncology combination study completes enrollment as cash falls to $457.4 million.
SEC filing
Latest
1 story
Sign inSign in1 story
Phase 3 asthma trials expand recruitment and an oncology combination study completes enrollment as cash falls to $457.4 million.
SEC filing